These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 17439900

  • 1. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, Tenaglia S, Di Filippo M, Calabresi P.
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [Abstract] [Full Text] [Related]

  • 2. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K, Reder AT.
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [Abstract] [Full Text] [Related]

  • 3. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
    Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S.
    Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
    [Abstract] [Full Text] [Related]

  • 4. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D, Mausner-Fainberg K, Urshansky N, Fahoum F, Karni A.
    J Neuroimmunol; 2009 Jun 25; 211(1-2):114-9. PubMed ID: 19419774
    [Abstract] [Full Text] [Related]

  • 5. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
    Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C, Nociti V, Tonali PA, Mirabella M.
    Clin Immunol; 2006 Jan 25; 118(1):77-82. PubMed ID: 16275091
    [Abstract] [Full Text] [Related]

  • 6. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.
    Azoulay D, Vachapova V, Shihman B, Miler A, Karni A.
    J Neuroimmunol; 2005 Oct 25; 167(1-2):215-8. PubMed ID: 16083971
    [Abstract] [Full Text] [Related]

  • 7. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 25; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 8. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
    Blanco Y, Moral EA, Costa M, Gómez-Choco M, Torres-Peraza JF, Alonso-Magdalena L, Alberch J, Jaraquemada D, Arbizu T, Graus F, Saiz A.
    Neurosci Lett; 2006 Oct 09; 406(3):270-5. PubMed ID: 16934924
    [Abstract] [Full Text] [Related]

  • 9. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 09; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 10. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
    Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M.
    J Neuroimmunol; 2008 Jul 15; 197(2):147-51. PubMed ID: 18555540
    [Abstract] [Full Text] [Related]

  • 11. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
    Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P, Telarico P, Cerasa A, Gioia MC, di Palma G, Quattrone A.
    Brain Res; 2009 Feb 23; 1256():123-8. PubMed ID: 19071096
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.
    Adv Ther; 2008 Jul 23; 25(7):658-73. PubMed ID: 18641926
    [Abstract] [Full Text] [Related]

  • 13. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T, Schwan M, Pollmächer T, Yassouridis A, Uhr M, Trenkwalder C, Weber F.
    Mult Scler; 2007 Nov 23; 13(9):1138-45. PubMed ID: 17967841
    [Abstract] [Full Text] [Related]

  • 14. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S, Hassinger S, Lindquist JA, Sailer M.
    Mult Scler; 2011 Jul 23; 17(7):851-66. PubMed ID: 21561957
    [Abstract] [Full Text] [Related]

  • 15. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 16. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
    Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Süssmuth S, Lauda F, Kapfer T, Fang L, Senel M, Brettschneider J.
    Eur Neurol; 2011 Sep 26; 65(3):164-9. PubMed ID: 21372576
    [Abstract] [Full Text] [Related]

  • 17. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, Perini P, Gallo P.
    Mult Scler; 2012 Apr 26; 18(4):418-24. PubMed ID: 21228025
    [Abstract] [Full Text] [Related]

  • 18. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
    Sarchielli P, Critelli A, Greco L, Sokola E, Floridi A, Gallai V.
    Cytokine; 2001 Jun 07; 14(5):294-8. PubMed ID: 11444910
    [Abstract] [Full Text] [Related]

  • 19. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Bornstein NM, Karni A.
    J Neuroimmunol; 2011 Mar 07; 232(1-2):171-8. PubMed ID: 21111488
    [Abstract] [Full Text] [Related]

  • 20. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
    Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP.
    Adv Ther; 2009 May 07; 26(5):552-62. PubMed ID: 19444392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.